Needham Maintains Alcon(ALC.US) With Buy Rating, Maintains Target Price $106
Alcon (ALC) Reports Q4 Earnings: What Key Metrics Have to Say
Alcon's Strong Q4 Performance and Market Share Gains Reinforce Buy Rating Despite Lower 2025 Guidance
Alcon | 6-K: Report of foreign private issuer (related to financial reporting)
GUIDANCE: (ALC) ALCON INC. INVESTORS Expects Fiscal Year 2025 Adjusted EPS Range $3.15 - $3.25
Alcon: Board Authorized the Repurchase of Up to $750M of the Company's Common Shrs >ALC.EB
Earnings Flash (ALC) ALCON Reports Q4 Adjusted EPS $0.72, Vs. FactSet Est of $0.71
Alcon 4Q EPS 57c >ALC.EB
Alcon 4Q Rev $2.5B >ALC.EB
Alcon Q4 2024 Adj. EPS $0.72 Beats $0.71 Estimate, Sales $2.477B Beat $2.466B Estimate
Press Release: Alcon Reports Full-Year 2024 Results, With Strong Top-line and Earnings Growth and Record Cash Generation
Here Are the Major Earnings After the Close Today
Earnings Scheduled For February 25, 2025
Swiss Equities Begin Week Little Changed; Belimo Shares Fall
Alcon Debut New Eye Drop Product in US
Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Longest Lasting Formula Yet
Stifel Maintains Alcon(ALC.US) With Buy Rating, Maintains Target Price $100
Earnings Preview: Alcon to Report Financial Results Pre-market on February 26
Alcon to Roll Out New Glaucoma, Ocular Hypertension Laser Therapy in US
Alcon Announces U.S. Launch of Voyager DSLT, First-of-its-Kind Treatment for Glaucoma and Ocular Hypertension